Cecolin 9 shows six-month immunogenicity data in single-dose HPV trial against Gardasil 9, with final results expected in ...

The MDT-BRIDGE trial's 142-patient neoadjuvant durvalumab dataset introduces a multidisciplinary reassessment architecture ...

Kos Biotechnology Partners funds Golden Age Health to accelerate rare disease access in Asia, closing treatment delays for ...

EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer, with strong disease control across histology subtypes ...

ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis trial, with potential for once-yearly dosing in ...

Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants ...

Citius Oncology reports preliminary LYMPHIR unit sales and vial orders for Q4 2026, signaling commercial momentum in the ...

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...

RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...

FDA AI Guidance requires clinical trial sponsors to validate algorithms before submission, shifting documentation and testing ...

AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most sponsors ...